- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07444372
Start der CPAP-Therapie bei Patienten mit obstruktiver Schlafapnoe nach Ablation von Vorhofflimmern (STOP-AFib)
Beginn der CPAP-Therapie bei Patienten mit obstruktiver Schlafapnoe nach Vorhofflimmerablation: Eine multizentrische, offene, randomisierte klinische Studie
Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.
This study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.
Participants will:
- Be randomly assigned to either the CPAP group or the usual care group.
- If in the CPAP group, use a CPAP device for 12 months.
- Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months after randomization.
- Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after randomization.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Atrial fibrillation (AF) is a common sustained cardiac arrhythmia, with recurrence rates of 20-45% after catheter ablation. Obstructive sleep apnea (OSA) is a common comorbidity and an important modifiable risk factor for post-ablation AF recurrence. Continuous positive airway pressure (CPAP) is the standard therapy for OSA, but its effect on reducing AF recurrence after ablation remains uncertain.This study aims to evaluate whether, in patients with OSA and AF who undergo catheter ablation, the postoperative CPAP treatment can increase the rate of no recurrence of atrial arrhythmia within one year compared to usual treatment. This prospective, multicenter, open-label, parallel-group randomized controlled trial will be conducted at approximately 20 centers in mainland China. Approximately 658 adults aged 18-75 years with persistent AF and diagnosed OSA who have successfully undergone first-time catheter ablation will be enrolled.
After confirmation of eligibility and informed consent, participants will be randomized in a 1:1 ratio to receive either CPAP therapy plus usual care or usual care alone. CPAP therapy will be provided for 12 months, with treatment parameters determined by pressure titration, and adherence monitored using device-recorded data. Participants in the usual care group will receive standard AF management and standardized education regarding OSA; additional OSA treatments outside the study protocol will be permitted and documented.All participants will receive guideline-directed medical therapy for AF.
Follow-up will last at least 12 months, with assessments at approximately 1, 3, 6, and 12 months after randomization. Atrial arrhythmia monitoring will be performed primarily using ambulatory ECG recorders.
The primary outcome is freedom from atrial arrhythmia recurrence within 12 months after randomization. Secondary outcomes include atrial arrhythmia recurrence patterns, arrhythmia-related interventions, atrial fibrillation burden, and changes in quality-of-life and psychological assessment scores.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Jiang Xie, Professor
- Telefonnummer: +86 64456360
- E-Mail: frank782008@aliyun.com
Studienorte
-
-
-
Tianjin, China
- Noch keine Rekrutierung
- Tianjin Medical University Second Hospital
-
Hauptermittler:
- Xiaoyun Zhao, Professor
-
Kontakt:
- Xiaoyun Zhao, Professor
- Telefonnummer: +86-022-88326681
- E-Mail: zxydoctor@163.com
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100029
- Rekrutierung
- Beijing Anzhen Hospital
-
Kontakt:
- Jiang Xie, Professor
- Telefonnummer: +86 64456360
- E-Mail: frank782008@aliyun.com
-
Hauptermittler:
- Jiang Xie, Professor
-
Hauptermittler:
- Shaoping Nie, Professor
-
Hauptermittler:
- Deyong Long, Professor
-
Beijing, Beijing Municipality, China, 100730
- Noch keine Rekrutierung
- Beijing Hospital
-
Kontakt:
- Wei Gong, Professor
- Telefonnummer: +86 85132266
- E-Mail: gongwei5180@bjhmoh.cn
-
Hauptermittler:
- Wei Gong, Professor
-
Beijing, Beijing Municipality, China, 102206
- Noch keine Rekrutierung
- Peking University International Hospital
-
Kontakt:
- Yanwen Jiang, Professor
- Telefonnummer: +86 01069006163
- E-Mail: jiangyanwen@pkuih.edu.cn
-
Hauptermittler:
- Yanwen Jiang, Professor
-
Beijing, Beijing Municipality, China, 100020
- Noch keine Rekrutierung
- Beijing Chaoyang Hospital, Capital Medical University
-
Kontakt:
- Zhiling Zhao, Professor
- Telefonnummer: +86-10-85231000
- E-Mail: cysleep@163.com
-
Hauptermittler:
- Zhiling Zhao, Professor
-
Beijing, Beijing Municipality, China, 100035
- Noch keine Rekrutierung
- Beijing Jishuitan Hospital
-
Kontakt:
- Yang Cheng, Professor
- Telefonnummer: +86 01058516688
- E-Mail: hengyang0323@outlook.com
-
Hauptermittler:
- Yang Cheng, Professor
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Noch keine Rekrutierung
- Fujian Medical University Union Hospital
-
Kontakt:
- Xiangqi Chen, Professor
- Telefonnummer: +86-591-83357896
- E-Mail: chxqq2003@126.com
-
Hauptermittler:
- Xiangqi Chen, Professor
-
Fuzhou, Fujian, China, 350004
- Noch keine Rekrutierung
- First Affiliated Hospital of Fujian Medical University
-
Kontakt:
- Ningfang Lian, Professor
- Telefonnummer: +86 059187981698
- E-Mail: 1533532863@qq.com
-
Hauptermittler:
- Ningfang Lian, Professor
-
Zhangzhou, Fujian, China, 363000
- Noch keine Rekrutierung
- Zhangzhou Hospital of Fujian Province
-
Kontakt:
- Li Lin, Professor
- Telefonnummer: +86-596-2082000
- E-Mail: linlid222@163.com
-
Hauptermittler:
- Li Lin, Professor
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Noch keine Rekrutierung
- People's Hospital of Guangxi Zhuang Autonomous Region
-
Kontakt:
- Mingming Zhao, Professor
- Telefonnummer: +86-771-2186076
- E-Mail: topabigale@163.com
-
Hauptermittler:
- Mingming Zhao, Professor
-
-
Hebei
-
Langfang, Hebei, China, 065000
- Noch keine Rekrutierung
- Langfang People's Hospital
-
Kontakt:
- Zengming Xue, Professor
- Telefonnummer: +86 03162369665
- E-Mail: xuezengming@163.com
-
Hauptermittler:
- Zengming Xue, Professor
-
Shijiazhuang, Hebei, China, 050000
- Rekrutierung
- Shijiazhuang Great Wall Hospital of Integrated Traditional Chinese and Western Medicine
-
Kontakt:
- Linyi Huang, Professor
- Telefonnummer: +86-0311-85837801
- E-Mail: 496777551@qq.com
-
Hauptermittler:
- Linyi Huang, Professor
-
Xingtai, Hebei, China, 055250
- Rekrutierung
- The Ninth Hospital of Xingtai
-
Kontakt:
- Zhanwei Liu, Professor
- Telefonnummer: +86-0319-4321827
- E-Mail: liuzhanweidf@sina.com
-
Hauptermittler:
- Zhanwei Liu, Professor
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150086
- Noch keine Rekrutierung
- Second Affiliated Hospital of Harbin Medical University
-
Kontakt:
- Wei Meng, Professor
- Telefonnummer: +86 045186296870
- E-Mail: mengweixq@163.com
-
Hauptermittler:
- Wei Meng, Professor
-
-
Henan
-
Shangqiu, Henan, China
- Noch keine Rekrutierung
- Shangqiu First People's Hospital
-
Kontakt:
- Renshan Niu, Professor
- Telefonnummer: +86-0370-3255630
- E-Mail: niurenshan1965@163.com
-
Hauptermittler:
- Renshan Niu, Professor
-
Zhengzhou, Henan, China, 450052
- Noch keine Rekrutierung
- The First Affiliated Hospital of Zhengzhou University
-
Kontakt:
- Gangqiong Liu
- Telefonnummer: +86-371-66913114
- E-Mail: doctorliu61352@163.com
-
Hauptermittler:
- Gangqiong Liu, Professor
-
-
Hubei
-
Wuhan, Hubei, China, 430014
- Noch keine Rekrutierung
- Wuhan No. 1 Hospital
-
Kontakt:
- Zhihua Yu, Professor
- Telefonnummer: +86 02785332144
- E-Mail: whyu027@163.com
-
Hauptermittler:
- Zhihua Yu, Professor
-
Wuhan, Hubei, China, 430056
- Noch keine Rekrutierung
- Wuhan Asia General Hospital
-
Kontakt:
- Ning Man, Professor
- Telefonnummer: +86-027-84788999
- E-Mail: Mannyl75@126.com
-
Hauptermittler:
- Ning Man, Professor
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Noch keine Rekrutierung
- The Second Xiangya Hospital of Central South University
-
Kontakt:
- Ruoyun Ouyang, Professor
- Telefonnummer: +86-731-85295888
- E-Mail: ouyangruoyun@csu.edu.cn
-
Hauptermittler:
- Ruoyun Ouyang, Professor
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Noch keine Rekrutierung
- The First Affiliated Hospital of Nanjing Medical University
-
Kontakt:
- Ning Ding, Professor
- Telefonnummer: +86 02568307346
- E-Mail: dingning@njmu.edu.cn
-
Hauptermittler:
- Ning Ding, Professor
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Noch keine Rekrutierung
- The First Hospital of Jilin University
-
Kontakt:
- Haibo Yuan, Professor
- Telefonnummer: +86-431-88782222
- E-Mail: hyuan@jlu.edu.cn
-
Hauptermittler:
- Haibo Yuan, Professor
-
-
Liaoning
-
Dalian, Liaoning, China, 116011
- Noch keine Rekrutierung
- First Affiliated Hospital of Dalian Medical University
-
Kontakt:
- Haiying Tang, Professor
- Telefonnummer: +86 0411836359632561
- E-Mail: doctortanghy@163.com
-
Hauptermittler:
- Haiying Tang, Professor
-
Shenyang, Liaoning, China, 110004
- Noch keine Rekrutierung
- Shengjing Hospital of China Medical University
-
Kontakt:
- Li Xiao, Professor
- Telefonnummer: +86-24-96615
- E-Mail: xiaolisy@163.com
-
Hauptermittler:
- Li Xiao, Professor
-
Shenyang, Liaoning, China, 110001
- Noch keine Rekrutierung
- First Affiliated Hospital of China Medical University
-
Kontakt:
- Wenyang Li, Professor
- Telefonnummer: +86 83282530
- E-Mail: 20122043@cmu.edu.cn
-
Hauptermittler:
- Wenyang Li, Professor
-
-
Shandong
-
Dongying, Shandong, China, 257034
- Noch keine Rekrutierung
- Shengli Oilfield Central Hospital
-
Kontakt:
- Xiangfei Liu, Professor
- Telefonnummer: +86-546-8551222
- E-Mail: zhaoyang20023903@126.com
-
Hauptermittler:
- Xiangfei Liu, Professor
-
Linyi, Shandong, China, 276003
- Noch keine Rekrutierung
- Linyi People's Hospital
-
Kontakt:
- Li Wei, Professor
- Telefonnummer: +86-539-8216261
- E-Mail: weilineu@163.com
-
Hauptermittler:
- Li Wei, Professor
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030001
- Noch keine Rekrutierung
- Second Hospital of Shanxi Medical University
-
Kontakt:
- Xiaoling Gao, Professor
- Telefonnummer: +86 03513362858
- E-Mail: yihexiyuan@qq.com
-
Hauptermittler:
- Xiaoling Gao, Professor
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300222
- Noch keine Rekrutierung
- Tianjin Chest Hospital
-
Kontakt:
- Fang Zhao, Professor
- Telefonnummer: +86-22-88185111
- E-Mail: zfangdoctortjxkyy@163.com
-
Hauptermittler:
- Fang Zhao, Professor
-
-
Yunnan
-
Kunming, Yunnan, China
- Noch keine Rekrutierung
- Yan'an Hospital of Kunming City
-
Kontakt:
- Xia Jiang, Professor
- Telefonnummer: +86-0871-63211073
- E-Mail: 378972370@qq.com
-
Hauptermittler:
- Xia Jiang, Professor
-
-
Zhejiang
-
Ningbo, Zhejiang, China, 315010
- Noch keine Rekrutierung
- First Affiliated Hospital of Ningbo University
-
Kontakt:
- Maoqing Tong, Professor
- Telefonnummer: +86 57487085588
- E-Mail: ganbaursy@163.com
-
Hauptermittler:
- Maoqing Tong, Professor
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Patients must meet all of the following conditions to be eligible for the study:
- Age 18-75 years.
- Patients with persistent AF who received catheter ablation for the first time.
- Diagnosed with OSA.
- Able to tolerate CPAP therapy.
- Capable of understanding and complying with the study protocol.
- Willing to sign the informed consent form.
Exclusion Criteria:
Patients meeting any of the following criteria will be excluded from the study:
- Secondary AF.
- Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).
- Left ventricular ejection fraction < 30%.
- Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).
- Pregnant or breastfeeding women.
- History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.
- History of stroke or transient ischemic attack within 6 months prior to screening.
- Perioperative complications related to the ablation procedure occurring prior to randomization.
- Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.
- Life expectancy < 1 year.
- Central sleep apnea.
- Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI > 30kg/m² and awake PaCO₂ > 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with > 1 episode of respiratory failure or hypercapnia.
- Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.
- Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.
- Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.
- Current participation in other drug or device trials.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: CPAP Group
Usual care combined with CPAP therapy. |
Participants receive CPAP therapy provided by the research team. Treatment parameters are determined following auto-titrating or manual pressure titration. Prior to treatment initiation, participants receive training on device usage, mask fitting and adjustment, equipment cleaning and maintenance, and data transmission methods. Study physicians and technicians provide support to address any CPAP-related discomfort. 'Good adherence' is defined as device usage of ≥ 4 hours per night on ≥ 70% of days. Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives. |
|
Aktiver Komparator: Usual Care Group
Standard of care for atrial fibrillation and usual care for OSA (health education). Researchers advise participants to visit sleep centers or pulmonology departments for further assessment/treatment at their own discretion, but do not intervene in their choice of OSA therapy or provide the study CPAP device. |
Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of freedom from atrial arrhythmia recurrence.
Zeitfenster: Within 12 months
|
Recurrence is defined as a composite of:
|
Within 12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Inzidenz jeglicher dokumentierter atrialer Arrhythmie (AF/AFL/AT) mit einer Dauer von ≥30 Sekunden.
Zeitfenster: Innerhalb von 12 Monaten (nach einer 3-monatigen Blanking-Periode).
|
Innerhalb von 12 Monaten (nach einer 3-monatigen Blanking-Periode).
|
|
|
Inzidenz von dokumentiertem AF mit einer Dauer von ≥30 Sekunden.
Zeitfenster: Innerhalb von 12 Monaten (nach einer 3-monatigen Blanking-Periode).
|
Innerhalb von 12 Monaten (nach einer 3-monatigen Blanking-Periode).
|
|
|
Inzidenz dokumentierter AT mit einer Dauer von ≥30 Sekunden.
Zeitfenster: Innerhalb von 12 Monaten (nach einer dreimonatigen Blanking-Periode).
|
Innerhalb von 12 Monaten (nach einer dreimonatigen Blanking-Periode).
|
|
|
Inzidenz dokumentierten AFLs mit einer Dauer von ≥30 Sekunden.
Zeitfenster: Innerhalb von 12 Monaten (nach einer 3-monatigen Blanking-Periode).
|
Innerhalb von 12 Monaten (nach einer 3-monatigen Blanking-Periode).
|
|
|
Anteil der Patienten, die Antiarrhythmika der Klasse I oder III verwenden.
Zeitfenster: Innerhalb von 12 Monaten (nach einer 3-monatigen Blanking-Periode).
|
Innerhalb von 12 Monaten (nach einer 3-monatigen Blanking-Periode).
|
|
|
Anteil der Patienten, die eine Kardioversion erhalten.
Zeitfenster: Innerhalb von 12 Monaten (nach einer 3-monatigen Karenzzeit).
|
Innerhalb von 12 Monaten (nach einer 3-monatigen Karenzzeit).
|
|
|
Anteil der Patienten, die sich einer wiederholten Katheterablation unterziehen.
Zeitfenster: Innerhalb von 12 Monaten.
|
Innerhalb von 12 Monaten.
|
|
|
AF-Belastung
Zeitfenster: Innerhalb von 12 Monaten.
|
Innerhalb von 12 Monaten.
|
|
|
Change in quality of life assessed by the Atrial Fibrillation Effect on Quality-of-Life questionnaire.
Zeitfenster: Baseline, Month 12.
|
Scores range from 0 to 100, where higher scores indicate a better quality of life. |
Baseline, Month 12.
|
|
Change in anxiety and depression assessed by the Hospital Anxiety and Depression Scale.
Zeitfenster: Baseline, Month 12.
|
Scores for both the anxiety and depression subscales range from 0 to 21, where higher scores indicate worse anxiety and depression. |
Baseline, Month 12.
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Caples SM, Mansukhani MP, Friedman PA, Somers VK. The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: A randomized controlled trial. Int J Cardiol. 2019 Mar 1;278:133-136. doi: 10.1016/j.ijcard.2018.11.100. Epub 2018 Nov 20.
- Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, Mehra R, Bozkurt B, Ndumele CE, Somers VK. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-e67. doi: 10.1161/CIR.0000000000000988. Epub 2021 Jun 21.
- Dretzke J, Chuchu N, Agarwal R, Herd C, Chua W, Fabritz L, Bayliss S, Kotecha D, Deeks JJ, Kirchhof P, Takwoingi Y. Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. Europace. 2020 May 1;22(5):748-760. doi: 10.1093/europace/euaa041.
- Sanchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, Sanchez-de-la-Torre A, Moncusi-Moix A, Torres G, Loffler K, Woodman R, Adams R, Labarca G, Dreyse J, Eulenburg C, Thunstrom E, Glantz H, Peker Y, Anderson C, McEvoy D, Barbe F. Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis. JAMA. 2023 Oct 3;330(13):1255-1265. doi: 10.1001/jama.2023.17465.
- Hunt TE, Traaen GM, Aakeroy L, Bendz C, Overland B, Akre H, Steinshamn S, Loennechen JP, Hegbom F, Broch K, Lie OH, Lyseggen E, Haugaa KH, Gullestad L, Anfinsen OG. Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: A randomized controlled trial. Heart Rhythm. 2022 Sep;19(9):1433-1441. doi: 10.1016/j.hrthm.2022.06.016. Epub 2022 Jun 16.
- Zhou Y, Yan M, Yuan J, Wang Y, Qiao S. Continuous Positive Airway Pressure Treatment Decreases the Risk of Atrial Fibrillation Recurrence in Patients with Obstructive Sleep Apnea after Radiofrequency Ablation. Int Heart J. 2022 Jul 30;63(4):716-721. doi: 10.1536/ihj.22-129. Epub 2022 Jul 14.
- Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP, Gersh BJ; ORBIT-AF Investigators. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2015 May;169(5):647-654.e2. doi: 10.1016/j.ahj.2014.12.024. Epub 2015 Feb 7.
- Deng F, Raza A, Guo J. Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis. Sleep Med. 2018 Jun;46:5-11. doi: 10.1016/j.sleep.2018.02.013. Epub 2018 Mar 22.
- de Heide J, Kock-Cordeiro DBM, Bhagwandien RE, Hoogendijk MG, van der Meer KC, Wijchers SA, Szili-Torok T, Zijlstra F, Lenzen MJ, Yap SC. Impact of undiagnosed obstructive sleep apnea on atrial fibrillation recurrence following catheter ablation (OSA-AF study). Int J Cardiol Heart Vasc. 2022 Mar 24;40:101014. doi: 10.1016/j.ijcha.2022.101014. eCollection 2022 Jun.
- Minami T, Yoshizawa T, Murase K, Komasa A, Aizawa T, Yamagami S, Tanaka M, Shizuta S, Sato S, Ono K, Hirai T, Kimura T, Chin K. Associations Among Sleep Apnea, Objective or Subjective Sleep Duration, and Recurrence of Atrial Fibrillation in Patients Who Undergo Radiofrequency Catheter Ablation for Persistent Atrial Fibrillation - A Prospective Observational Study. Circ J. 2025 Jan 24;89(2):184-194. doi: 10.1253/circj.CJ-24-0537. Epub 2024 Nov 12.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Erkrankungen des Nervensystems
- Herz-Kreislauf-Erkrankungen
- Psychische Störungen
- Pathologische Prozesse
- Herzkrankheiten
- Erkrankungen der Atemwege
- Atemstörungen
- Apnoe
- Schlafstörungen, intrinsisch
- Dyssomnien
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Vorhofflimmern
- Schlafapnoe-Syndrome
- Schlafapnoe, obstruktiv
- Schlaf-Wach-Störungen
- Arrhythmien, Herz
- Therapeutika
- Atemwegsmanagement
- Atemtherapie
- Respiration mit positiver Druck
- Atmung, künstlich
- Kontinuierlicher positiver Atemwegsdruck
Andere Studien-ID-Nummern
- KS2025046
- 2024ZD0529100 (Andere Zuschuss-/Finanzierungsnummer: Development Center for Medical Science & Technology National Health Commission of the People's Republic of China)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .